<DOC>
	<DOCNO>NCT02057250</DOCNO>
	<brief_summary>Primary Objective : To collect real-use data sarilumab auto-injector use rheumatoid arthritis ( RA ) patient . Secondary Objective : To compare pharmacokinetic ( PK ) exposure sarilumab administer AID versus prefilled syrinx ( PFS ) .</brief_summary>
	<brief_title>To Evaluate Sarilumab - SAR153191 ( REGN88 ) - Auto-injector Device In Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Total study duration 74 week : screen 4 week , AID assessment phase 12 week , extension phase 52 week , post-treatment follow-up 6 week . For patient enter extension phase , total study duration 22 week ( screen , AID assessment phase follow-up ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Inclusion criterion : Diagnosis rheumatoid arthritis ( RA ) , ≥3 month disease duration Patient willing able selfinject Continuous treatment 1 combination nonbiologic DMARDs ( except leflunomide combination methotrexate ) Moderatetoseverely active RA Exclusion criterion : Patients &lt; 18 year Prior treatment antiinterleukin 6 ( IL6 ) IL6 receptor ( IL6R ) antagonists Treatment tumor necrosis factor ( TNF ) antagonists Treatment RAdirected biologic agent TNFα antagonist mechanism follow : Anakinra , Abatacept , Rituximab celldepleting agent Prior treatment Janus kinase inhibitor The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>